RECURSION PHARMACEUTICALS, INC. (RXRX) earnings date
Feb 26, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 40% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 2, 2026 | after close | 33 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | before open | 36 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | before open | 36 | 8-K |
| Q4 FY2025 | Wed, Feb 25, 2026 | before open | 56 | 8-K |
| Q3 FY2025 | Wed, Nov 5, 2025 | before open | 36 | 8-K |
| Q2 FY2025 | Tue, Aug 5, 2025 | before open | 36 | 8-K |
| Q1 FY2025 | Mon, May 5, 2025 | before open | 35 | 8-K |
| Q4 FY2024 | Fri, Feb 28, 2025 | before open | 59 | 8-K |
What they guided beta
| Q3 FY2026 | "Sanofi options the first development candidate from Recursion collaboration , a potential first-in-class, dual targeting inhibitor oral small molecule in immunology, which will now advance into Sanofi’s portfolio, with Phase 1 clinical study expected to begin in 2027." exhibit |
| Q3 FY2026 | "Expected cash runway extended into 2029 , including proceeds from the October 2026 follow-on offering; 2026 cash operating expense guidance reiterated at less than $375 million, with 2027 guidance of less than $360 million." exhibit |
| Q3 FY2026 | "The Company anticipates initiating a registrational trial in the second half of 2027, pending ongoing FDA discussions, and will provide additional details later this year." exhibit |
| Q3 FY2026 | "Preliminary dose expansion data in endometrial cancer are expected in the second half of 2027." exhibit |
| Q3 FY2026 | "The candidate has now been added to Sanofi’s development pipeline and is expected to enter Phase 1 clinical trials in 2027, with Sanofi funding and leading further development and commercialization to advance the program toward patients." exhibit |
| Q2 FY2026 | "Reduced 2026 cash operating expense guidance to <$375 million (from <$390 million) SALT LAKE CITY, August 5, 2026 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates highlighting strong continued pipeline execution, clinical progress and platform advancement, as well as financial results for its second quarter ended June 30, 2026." exhibit |
| Q2 FY2026 | "Session date and time: Monday November 2, 2026; 13:30 - 15:00 MST Phase 1/2 Trial Initiation for REC-7735 expected in 2H26:" exhibit |
| Q2 FY2026 | "With the IND cleared, the Phase 1/2 ZINNIA clinical study for patients with select PIK3CA H1047R-mutant solid tumors will be initiated in the second half of 2026 For the rest of the portfolio, programs continue to progress as planned." exhibit |
| Q2 FY2026 | "Based on current operating plans with no additional financing, the Company continues to expect its cash runway to extend into early 2028." exhibit |
| Q2 FY2026 | "The Company is lowering its cash operating expense guidance for the full year 2026 by $15 million to $375 million based on additional identified operating efficiencies." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/RXRX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/RXRX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/RXRX/"><img src="https://veritasdata.dev/embed/RXRX.svg" alt="RXRX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/RXRX/)
Script
<script async src="https://veritasdata.dev/embed/RXRX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/RXRX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.